Vascular Dementia Market Report 2025

This Vascular Dementia market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The vascular dementia market size has grown rapidly in recent years. It will grow from $2.92 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth during the historical period can be attributed to higher healthcare spending, an increase in the number of patients diagnosed with vascular dementia, a rise in healthcare professionals, the expansion of public health initiatives, and a growing prevalence of diabetes.

The vascular dementia market size is expected to see rapid growth in the next few years. It will grow to $5.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The expected growth in the forecast period is driven by a greater awareness of vascular dementia, rising healthcare investments, an aging population, a higher incidence of cardiovascular diseases, and an increase in the prevalence of high blood pressure. Key trends in the forecast period include technological advancements, personalized care plans, telemedicine, gene therapy, and the integration of artificial intelligence.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the vascular dementia market. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, arrhythmias, and hypertension. Factors such as unhealthy lifestyles, poor dietary habits, physical inactivity, heightened stress levels, aging populations, and an increase in risk factors such as obesity, diabetes, and hypertension are contributing to the rise in cardiovascular diseases. These conditions increase the risk of vascular dementia by disrupting blood flow to the brain, which can lead to cognitive decline and brain cell damage due to insufficient oxygen and nutrients. For example, according to the British Heart Foundation in September 2024, approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with around 4 million men and 3.6 million women living with these conditions. These diseases are responsible for 27% of all deaths in the UK, totaling over 170,000 deaths annually, or about 480 deaths per day. As a result, the increasing prevalence of cardiovascular diseases is driving the growth of the vascular dementia market.

Companies in the vascular dementia market are focusing on developing new therapies, such as multimodal therapies, to maintain their competitive edge. Multimodal therapies combine various treatment approaches, including medications, physical therapy, and psychological interventions, to provide comprehensive treatment. For example, in January 2023, Moleac, a biopharmaceutical company based in Singapore, launched CognivAiD, an evidence-based treatment specifically designed for vascular dementia (VaD), a condition with few therapeutic options. This product combines active extracts from ginkgo, ginseng, and saffron, which have been shown to slow cognitive decline in VaD patients. The multimodal action of CognivAiD addresses key mechanisms of vascular dementia, such as vascular protection, vasoregulation, and neuroinflammation. Supported by extensive clinical trials and a strong safety profile, CognivAiD offers a promising new treatment for individuals with VaD.

In November 2023, Merck, a US-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undisclosed amount. This acquisition is intended to accelerate the development of small-molecule therapeutics targeting neurodegenerative diseases, including Parkinson's disease and dementia. Caraway Therapeutics Inc. is a biopharmaceutical company based in the US, specializing in drug discovery and development for dementia.

Major players in the vascular dementia market are Intermountain Healthcare Inc., CSPC Ouyi Pharmaceutical Co. Ltd., Duke Health, Massachusetts General Hospital, Emory Healthcare Inc., Apollo Hospitals Enterprise Limited, Amedisys Inc., Northwestern Memorial HealthCare, IBS Hospitals Pvt. Ltd., Resverlogix Corp., ProNeurogen Inc., Cyclerion Therapeutics Inc., Aribio Inc., Pinteon Therapeutics Inc., Dementech Neurosciences Ltd., Moleac Pte. Ltd., Isaac Health Inc., Cadabam’s Group of Hospitals, Alpha Cognition Inc., and Citi Health.

North America was the largest region in the vascular dementia market in 2024. The regions covered in vascular dementia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vascular dementia is a form of cognitive decline caused by reduced blood flow to the brain, often resulting from strokes or other vascular issues. This condition leads to memory loss and impaired thinking. Treatment for vascular dementia primarily focuses on managing underlying vascular conditions, such as controlling high blood pressure, diabetes, and cholesterol, along with promoting a healthy lifestyle to enhance brain health and slow the disease's progression.

Key products in the treatment of vascular dementia include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies are designed to target specific proteins or molecules related to the disease. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are intended for use in hospitals, clinics, rehabilitation centers, and specialty clinics.

The vascular dementia market research report is one of a series of new reports that provides vascular dementia market statistics, including vascular dementia industry global market size, regional shares, competitors with a vascular dementia market share, detailed vascular dementia market segments, market trends and opportunities, and any further data you may need to thrive in the vascular dementia industry. This vascular dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vascular dementia market consists of revenues earned by entities providing services such as diagnosis, treatment, care management, and support for individuals. The market value includes the value of related goods sold by the service provider or included within the service offering. The vascular dementia market includes sales of assistive devices, cognitive enhancers, and diagnostic tools. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including healthcare providers, wholesalers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.